VIRX (Viracta Therapeutics) Insider Ownership: 3.06 % (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Viracta Therapeutics Insider Ownership?

Viracta Therapeutics VIRX Insider Ownership is 3.06 % as of Sep. 15, 2026.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Viracta Therapeutics's insider ownership is 3.06%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Viracta Therapeutics's Institutional Ownership is 0.39%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Viracta Therapeutics's Float Percentage Of Total Shares Outstanding is 78.83%.

Viracta Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Viracta Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viracta Therapeutics Insider Ownership Chart

Viracta Therapeutics Historical Data

The historical data trend for Viracta Therapeutics can be seen below:

2025-02-28 2025-03-31 2025-04-30 2025-05-31 2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30
Insider Ownership 3.06 3.06 3.06 3.06 3.06 3.06 3.06 3.06 3.06 3.06

Viracta Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 3.06 % mean?
Viracta Therapeutics (VIRX) has a Insider Ownership of 3.06 % as of Sep. 15, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Viracta Therapeutics and its competitors.
Is Viracta Therapeutics' Insider Ownership too high?
Viracta Therapeutics' current Insider Ownership is 3.06 %.
How does Viracta Therapeutics' Insider Ownership compare to TSOI and CYTOF?
Viracta Therapeutics' Insider Ownership of 3.06 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Viracta Therapeutics and its competitors. Viracta Therapeutics's current Insider Ownership is 3.06 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viracta Therapeutics stock overvalued right now?
Viracta Therapeutics (VIRX) has a current Insider Ownership of 3.06 %. The current Insider Ownership is 3.06 %. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Viracta Therapeutics (VIRX), the current Insider Ownership is 3.06 % as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viracta Therapeutics Business Description

Address 2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.